In all, 18 different HCC cases, 23 CC cases and 20 RCC cases containing both (adjacent) benign and tumor components were labeled with antibodies against MAL2 and Ki-67 (to assess the proliferative index). This evidence concerns the gene MAL2 and cholangiocarcinoma.